Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure

Pharmacotherapy

Volumn 24, Issue 6, 2004, Pages 750-756

  Cavallari, Larisa H ^a   Fashingbauer, Lucy A ^a   Beitelshees, Amber L ^a   Groo, Vicki L ^a,c   Southworth, Mary R ^a,b   Viana, Marlos A G ^b   Williams, Randall E ^c,d   Dunlap, Stephanie H ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c Division of Cardiology   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Heart failure; Potassium supplementation; Racial differences; Serum potassium concentration; Spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; LISINOPRIL; LOSARTAN; METOPROLOL; POTASSIUM; SPIRONOLACTONE;

ADULT; AFRICAN AMERICAN; AGED; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIURESIS; DOSE RESPONSE; FEMALE; HEART FAILURE; HOMEOSTASIS; HUMAN; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; POTASSIUM TRANSPORT; RACE DIFFERENCE; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIETARY SUPPLEMENTS; DIURETICS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; POTASSIUM; RETROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 2942625480     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.8.750.36076     Document Type: Review

References (22)

1. American Heart Association. 2003 heart and stroke statistical update. Dallas, TX: American Heart Association, 2002.
2. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16.
3. Vaccarino V, Gahbauer E, Kasl SV, Charpentier PA, Acampora D, Krumholz HM. Differences between African Americans and whites in the outcome of heart failure: evidence for a greater functional decline in African Americans. Am Heart J 2002;143:1058-67.
4. Philbin EF, DiSalvo TG. Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. Am J Cardiol 1998;82:76-81.
5. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-20.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17.
7. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2001;104:2996-3007.
8. Fleiss JL. Statistical methods for rates and proportions, 2nd ed. New York: John Wiley & Sons, 1981.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: vasodilator-heart failure trial study group. J Card Fail 1999;5:178-87.
11. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Department of Veterans Affairs cooperative study group on antihypertensive agents. Am J Hypertens 1995;8:189-92.
12. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
13. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002;40:311-17.
14. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.
15. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16.
16. Pratt JH, Manatunga AK, Bloem LJ, Li W. Racial differences in aldosterone excretion: a longitudinal study in children. J Clin Endocrinol Metab 1993;77:1512-15.
17. Manatunga AK, Reister TK, Miller JZ, Pratt JH. Genetic influences on the urinary excretion of aldosterone in children. Hypertension 1992;19:192-7.
18. Fisher ND, Gleason RE, Moore TJ, Williams GH, Hollenberg NK. Regulation of aldosterone secretion in hypertensive blacks. Hypertension 1994;23:179-84.
19. El-Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001;37:845-50.
20. Ford ES. Race, education, and dietary cations: findings from the third national health and nutrition examination survey. Ethn Dis 1998;8:10-20.
21. Ganguli MC, Grimm RH Jr, Svendsen KH, Flack JM, Grandits GA, Elmer PJ. Higher education and income are related to a better Na:K ratio in blacks: baseline results of the treatment of mild hypertension study (TOMHS) data. Am J Hypertens 1997;10:979-84.
22. Collins-Schramm HE, Phillips CM, Operario DJ, et al. Ethnic-difference markers for use in mapping by admixture linkage disequilibrium. Am J Hum Genet 2002;70:737-50.